Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Scientific Reports
|
March 31, 2026
Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant tuberculosis patients
Bern-Thomas Nyang'wa, Ilaria Motta, Ronelle Moodliar, et al.
Nature Communications
|
April 1, 2022
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Vincent Pavot, Catherine Berry, Michael Kishko, et al.
Nature Communications
|
March 9, 2023
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates
Vincent Pavot, Catherine Berry, Michael Kishko, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 29, 2024
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL
Tim Crocker-Buque, Nathalie Lachenal, Cindy Narasimooloo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 24, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis
Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, et al.
Plos Pathogens
|
October 3, 2013
Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein
Nicholas Glanville, Gary R McLean, Bruno Guy, et al.
ERJ Open Research
|
February 15, 2021
Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
Philipp du Cros, Atadjan Khamraev, Zinaida Tigay, et al.
Communications Medicine
|
May 26, 2023
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters
Catherine Berry, Vincent Pavot, Natalie G Anosova, et al.
The Lancet. Respiratory Medicine
|
November 19, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
The New England Journal of Medicine
|
December 22, 2022
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Scientific Reports
|
March 31, 2026
Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant tuberculosis patients
Bern-Thomas Nyang'wa, Ilaria Motta, Ronelle Moodliar, et al.
Nature Communications
|
April 1, 2022
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Vincent Pavot, Catherine Berry, Michael Kishko, et al.
Nature Communications
|
March 9, 2023
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates
Vincent Pavot, Catherine Berry, Michael Kishko, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 29, 2024
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL
Tim Crocker-Buque, Nathalie Lachenal, Cindy Narasimooloo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 24, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis
Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, et al.
Plos Pathogens
|
October 3, 2013
Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein
Nicholas Glanville, Gary R McLean, Bruno Guy, et al.
ERJ Open Research
|
February 15, 2021
Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
Philipp du Cros, Atadjan Khamraev, Zinaida Tigay, et al.
Communications Medicine
|
May 26, 2023
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters
Catherine Berry, Vincent Pavot, Natalie G Anosova, et al.
The Lancet. Respiratory Medicine
|
November 19, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
The New England Journal of Medicine
|
December 22, 2022
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, et al.
Page
of 4